Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TQ0242 |
Fenebrutinib
GDC-0853 |
BTK | Angiogenesis; Tyrosine Kinase/Adaptors |
Fenebrutinib (GDC-0853) 是一种选择性的、有效的、具有口服活性的、非共价的布鲁顿酪氨酸激酶抑制剂,对野生型 Btk,及突变型 C481S,C481R,T474I,T474M 的 Ki 分别为 0.91 nM,1.6,1.3,12.6 和 3.4 nM。有用于类风湿关节炎和系统性红斑狼疮研究的潜力。 | |||
TQ0242L |
Fenebrutinib HCl
GDC 0853,RG 7845,GDC-0853,GDC0853,RG7845,RG-7845 |
||
Fenebrutinib is orally available inhibitor of Bruton's tyrosine kinase (BTK) with antineoplastic activity. Upon administration, GDC-0853 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This |